About DST
DST is a Healthcare company based in Schwerin (Germany) founded in 2005, and was acquired by AESKU in April 2017. It operates as an innovative in-vitro diagnostic solutions are developed by DST. It operates on a Professional Services and Reseller / Distribution model. The company has 42 employees. DST offers products and services including FastCheckPOC 20 Allergy Rapid Test, ELISA Kits for IgE Detection, NutriSMART Food Intolerance Rapid Test, and Allergen Extracts. Its focus areas include Diagnostics and In-Vitro Diagnostics. Its legal entity is DST Diagnostische Systeme & Technologien GmbH. Its competitors include Allergy Amulet, YorkTest, Microtest Diagnostics, ATANIS Biotech and Immunovent and 3 more; 3 of its 8 listed competitors have raised funding.
Company details
In-vitro diagnostic solutions are developed and manufactured by DST, specializing in allergy and food intolerance diagnostics. Over 600 high-quality allergens for food, respiratory, and environmental testing are produced at their facility in Schwerin, Germany. Point-of-care and laboratory testing products, including rapid tests and ELISA kits, are offered to healthcare practitioners and laboratories worldwide. Custom solutions and patient sample collection kits are also provided to meet diverse diagnostic needs in the healthcare sector.
- Headquarters Schwerin, Germany
- Employees 42
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website dst-diagnostic.com
- Social LinkedIn
- Acquired by AESKU (Apr 2017)
- Legal Name Dst Diagnostische Systeme & Technologien Gmbh
Products & Services of DST
DST offers a comprehensive portfolio of products and services, including FastCheckPOC 20 Allergy Rapid Test, ELISA Kits for IgE Detection, NutriSMART Food Intolerance Rapid Test, and Allergen Extracts.
Rapid test for allergy detection in point-of-care settings.
Kits used for detecting specific IgE in labs.
Rapid test for identifying food intolerance in patients.
Extracts for testing over 600 allergen types.
Investors in DST
DST has secured backing from 1 investor. Prominent investors backing the company include AESKU.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Offers diagnostic test kits and automation for medical laboratories worldwide. | 2003 | aesku.com | Oakland, United States |
Investor details for DST
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of DST
2 dated milestones of DST across 12 years, from founding to its latest funding, stage changes and deals.
- Founded DST is founded.
- Exit Acquired by AESKU.
Competitors of DST
DST has 8 listed competitors in our database, 3 of them funded. They include Allergy Amulet, YorkTest, Microtest Diagnostics, ATANIS Biotech and Immunovent, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| allergyamulet.com | 2016 | Madison, United States | $12.57M | – | Portable food allergen sensors are offered via an online platform. | |
| yorktest.com | 1982 | York, United Kingdom | $12.03M | 38 | At-home food and allergy test kits are developed by YorkTest. | |
| microtestdx.com | 2002 | London, United Kingdom | $2.5M | 6 | Functions as an automated allergy testing service. | |
| atanis-biotech.com | 2021 | Sursee, Switzerland | – | – | Developer of a cell-based assay for the diagnosis of allergies | |
| immunovent.com | 2012 | New York, United States | – | – | Diagnostic tests for allergies are developed using mucosal brush samples. | |
| macroarraydx.com.ua | 2016 | Kiev, Ukraine | – | – | Allergen analyzers are provided for in-vitro IgE level determination. | |
| allergenis.com | 2017 | Hatfield, United States | – | – | Develops accurate allergy testing solutions for healthcare providers and patients. | |
| bangqibio.tcc.mode | 2020 | Suzhou, China | – | – | Instruments and reagents for immune disorder diagnosis are developed. |
Detailed competitors of DST
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as DST (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about DST
DST was founded in 2005.
DST is headquartered in Schwerin, Germany. It is registered at Schwerin, Mecklenburg-vorpommern, Germany.
DST has 42 employees.
In-vitro diagnostic solutions are developed and manufactured by DST, specializing in allergy and food intolerance diagnostics. Over 600 high-quality allergens for food, respiratory, and environmental testing are produced at their facility in Schwerin, Germany. Point-of-care and laboratory testing products, including rapid tests and ELISA kits, are offered to healthcare practitioners and laboratories worldwide. Custom solutions and patient sample collection kits are also provided to meet diverse diagnostic needs in the healthcare sector.
DST's top competitors include Allergy Amulet, ATANIS Biotech and YorkTest.
DST offers FastCheckPOC 20 Allergy Rapid Test, ELISA Kits for IgE Detection, NutriSMART Food Intolerance Rapid Test, and Allergen Extracts.
DST has 1 investor. Key investors include AESKU.
DST operates through Dst Diagnostische Systeme & Technologien Gmbh.
Yes. DST was acquired by AESKU in April 2017.